1. Home
  2. TPG vs TGTX Comparison

TPG vs TGTX Comparison

Compare TPG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TPG Inc.

TPG

TPG Inc.

N/A

Current Price

$50.60

Market Cap

7.0B

Sector

Finance

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$49.90

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TPG
TGTX
Founded
1992
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
7.6B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
TPG
TGTX
Price
$50.60
$49.90
Analyst Decision
Buy
Strong Buy
Analyst Count
15
5
Target Price
$61.20
$49.80
AVG Volume (30 Days)
2.4M
2.3M
Earning Date
05-01-2026
05-04-2026
Dividend Yield
4.89%
N/A
EPS Growth
207.14
1746.67
EPS
0.17
0.17
Revenue
$4,670,212,000.00
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
$19.79
$26.69
P/E Ratio
$106.82
$290.41
Revenue Growth
33.43
N/A
52 Week Low
$36.95
$26.76
52 Week High
$70.38
$59.30

Technical Indicators

Market Signals
Indicator
TPG
TGTX
Relative Strength Index (RSI) 73.38 44.60
Support Level $38.68 $28.57
Resistance Level $69.28 $58.08
Average True Range (ATR) 1.88 2.39
MACD 0.69 -0.64
Stochastic Oscillator 94.39 37.80

Price Performance

Historical Comparison
TPG
TGTX

About TPG TPG Inc.

TPG Inc is an alternative asset management firm. It invests across five multi-product platforms, namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, market solutions, innovation, and inclusion.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: